Literature DB >> 3594392

Selection of initial therapy for renal cell carcinoma.

J B deKernion, E Mukamel.   

Abstract

Complete surgical excision is the only effective method of treatment for renal cell carcinoma (RCC) and patients with extensive regional or distant metastases are incurable by any means. Accurate preoperative staging is therefore of critical importance, and computerized tomography and magnetic resonance imaging are the most accurate staging modalities. The traditional operative procedure for RCC has been the radical nephrectomy with excision of Gerota's fascia and its contents, resulting in a 60% to 70% 5-year survival of patients with localized tumors (T1-2 and N0 and M0). Extensive lymphadenectomy has not appreciably improved the cure rate. Indeed, less aggressive surgery has been recently proposed by some authors, based on the excellent results achieved after partial nephrectomy or for tumors in solitary kidneys, with survival after partial nephrectomy or enucleation similar to that after radical nephrectomy. Preoperative adjuvants such as angioinfarction or radiotherapy have not increased survival or local tumor control, and no regional or systemic postoperative adjuvant has proven to be of value. Until further data is accumulated, radical nephrectomy remains the treatment of choice for localized RCC.

Entities:  

Mesh:

Year:  1987        PMID: 3594392     DOI: 10.1002/1097-0142(19870801)60:3+<539::aid-cncr2820601517>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Significance of angiogenesis and microvascular invasion in renal cell carcinoma.

Authors:  Yoram Dekel; Rumelia Koren; Valentina Kugel; Pinhas M Livne; Rivka Gal
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

2.  Differential sensitivity of renal cell carcinoma xenografts towards therapy with interferon-alpha, interferon-gamma, tumor necrosis factor and their combinations.

Authors:  A J Beniers; R J van Moorselaar; W P Peelen; F M Debruyne; J A Schalken
Journal:  Urol Res       Date:  1991
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.